Correction to: Acta Pharmacologica Sinica https://doi.org/10.1038/s41401-021-00640-5, Published online 25 March 2021
The authors regret that the acknowledgments section of the original manuscript was incorrect. The corrected acknowledgements are shown below.
This work was supported by the National Natural Science Foundation of China (Grant Nos. 81974507 and 81773794) and the Science and Technology Program of Guangzhou City, China (Grant No. 201903010087).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Zhao, Za., Jiang, Y., Chen, Yy. et al. Author Correction: CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia. Acta Pharmacol Sin 43, 1884 (2022). https://doi.org/10.1038/s41401-022-00872-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41401-022-00872-z
